Skip to main content
. Author manuscript; available in PMC: 2015 Sep 23.
Published in final edited form as: Immunotherapy. 2014;6(6):737–753. doi: 10.2217/imt.14.35

Table 2.

Select clinical trials of everolimus (RAD-001) in glioblastoma.

Study (year) Phase Dose (n) PR (%) OS PFS Ref.
Kreisl et al. (2009) Pilot DE PO (n = 2);
70 mg/week PO (n = 20)		 14 Median: 5.8 months;
6-month: N/A		 Median: 2.6 months;
6-month: 4.5%		 [18]
Chinnaiyan et al. (2013) I 2.5 mg/day PO (n = 8);
5 mg /day PO (n = 9);
10 mg/day PO (n = 8)		 N/A Median: N/A;
6-month: 100%		 Median: N/A;
6-month: N/A		 [19]
Sarkaria et al. (2011) I 30 mg/week PO (n = 6);
50 mg/week PO (n = 6);
70 mg/week PO (n = 6)		 11 Median: N/A;
6-month: N/A		 Median: N/A;
6-month: N/A		 [22]
Mason et al. (2012) I 2.5 mg/day PO (n = 5);
5 mg/day PO (n = 15);
10 mg/day PO (n = 12)		 11 Median: N/A;
6-month: N/A		 Median: N/A;
6-month: N/A		 [21]
Hainsworth et al. (2012) II 10 mg/day PO (n = 57) 61 Median: 13.9 months;
6-month: N/A		 Median: 11.3 months;
6-month: 73%		 [20]

DE: Dose escalation; N/A: Not assessed; OS: Overall survival; PFS: Progression-free survival; PO: Per oral; PR: Partial response.